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Background: Virus-specific T-cells (VSTs) proliferate exponentially after adoptive transfer into hematopoietic stem cell
transplant (HSCT) recipients, eliminate virus infections, then persist and provide long-term protection from viral disease.
If VSTs behaved similarly when modified with tumor-specific chimeric antigen receptors (CARs), they should have
potent anti-tumor activity. This theory was evaluated by Cruz et al. in a previous clinical trial with CD19.CAR-modified
VSTs, but there was little apparent expansion of these cells in patients. In that study, VSTs were gene-modified on day
19 of culture and we hypothesized that by this time, sufficient T-cell differentiation may have occurred to limit the
subsequent proliferative capacity of the transduced T-cells. To facilitate the clinical testing of this hypothesis in a project
supported by the NHLBI-PACT mechanism, we developed and optimized a good manufacturing practices (GMP)
compliant method for the early transduction of VSTs directed to Epstein-Barr virus (EBV), Adenovirus (AdV) and
cytomegalovirus (CMV) using a CAR directed to the tumor-associated antigen disialoganglioside (GD2).
Results: Ad-CMVpp65-transduced EBV-LCLs effectively stimulated VSTs directed to all three viruses (triVSTs). Transduction
efficiency on day three was increased in the presence of cytokines and high-speed centrifugation of retroviral supernatant
onto retronectin-coated plates, so that under optimal conditions up to 88% of tetramer-positive VSTs expressed the
GD2.CAR. The average transduction efficiency of early-and late transduced VSTs was 55 ± 4% and 22 ± 5% respectively,
and early-transduced VSTs maintained higher frequencies of T cells with central memory or intermediate memory
phenotypes. Early-transduced VSTs also had higher proliferative capacity and produced higher levels of TH1 cytokines
IL-2, TNF-α, IFN-γ, MIP-1α, MIP-1β and other cytokines in vitro.
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Conclusions: We developed a rapid and GMP compliant method for the early transduction of multivirus-specific T-cells
that allowed stable expression of high levels of a tumor directed CAR. Since a proportion of early-transduced CAR-VSTs
had a central memory phenotype, they should expand and persist in vivo, simultaneously protecting against infection
and targeting residual malignancy. This manufacturing strategy is currently under clinical investigation in patients
receiving allogeneic HSCT for relapsed neuroblastoma and B-cell malignancies (NCT01460901 using a GD2.CAR and
NCT00840853 using a CD19.CAR).
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A major problem with chimeric antigen receptor (CAR)-
modified T-cells for the treatment of solid tumors is their
lack of in vivo proliferation [1,2]. Even when costimulatory
endodomains are incorporated into CARs, CAR-T-cells
may fail to proliferate in the presence of immunosuppres-
sive tumors that not only lack costimulatory ligands but
actively inhibit T-cell proliferation by expressing inhibitory
ligands, such as PD-L1 and secreting inhibitory cytokines
such as TGF-β [3-5]. By contrast to tumors, viruses are
highly immunostimulatory and T-cells with native TCR
specificity for viruses (VSTs) proliferate exponentially after
infusion into HSCT recipients because patients are lym-
phopenic and viruses are poorly controlled, increasing the
abundance of viral antigens [6]. We reasoned that if VSTs
were engrafted with tumor-specific CARs, then extratu-
moral stimulation by endogenous viruses would ensure
CAR-T-cell expansion in vivo and might even restore the
function of T-cells anergized by the tumor. Hence CAR-
VSTs could both protect against viral infections after
HSCT and eliminate residual tumor.
In a previous clinical trial we tested the hypothesis
that extratumoral stimulation by an endogenous virus
would ensure CAR-T-cell expansion in vivo in children
with relapsed neuroblastoma infused with autologous
EBV-specific T-cells (EBVSTs) genetically modified to
express a CAR specific for GD2, a disialoganglioside that
is highly expressed by this tumor [1,2]. We expected that
endogenous EBV would provide in vivo stimulation of
GD2.CAR-modified EBVSTs, increasing their expansion
and anti-tumor function relative to similarly-transduced
CD3-activated T-cells (GD2.CAR-ATCs). In this original
study, each T-cell component expressed a GD2.CAR
that differed only in a few non-coding nucleotides that
allowed us to compare the fate of infused GD2.CAR-
ATCs and GD2.CAR-EBVSTs in each patient treated.
This combination of T-cells was clinically effective,
producing tumor responses in 5 of 11 patients and
complete responses in three. However, although trans-
duced EBVSTs were detected at higher levels than trans-
duced ATCs in the six weeks following infection, they
did not apparently expand in numbers, at least asmeasured in the circulation, and tumor responses were
associated with the long-term persistence of either
population, albeit at low levels. Hence it was unclear
which population was responsible for the clinical
responses.
As an National Heart, Lung, and Blood Institute
(NHLBI)-funded Production Assistance for Cell Therapies
(PACT) site, we were charged with the production of
donor-derived T cells specific for EBV, CMV and adeno-
virus (triVSTs) transduced with the first generation
GD2.CAR, for pediatric patients receiving haploidentical
HSCT for the treatment of relapsed neuroblastoma at the
Children’s Mercy Hospital, Kansas City, MO (Principle
Investigator Dr. GD Myers, NCT01460901). In this new
protocol, the intent was to determine if infusion of
GD2.CAR-triVSTs after T-cell depleted HSCT could over-
come the previous lack of expansion by providing a
lymphopenic environment in which homeostatic cytokines
are in excess and viruses are poorly controlled and there-
fore more likely to stimulate CAR-modified VSTs. The
use of T-cells specific for three viruses rather than one
should increase the chances that T-cells would be stimu-
lated after HSCT, since CMV, EBV and adenoviruses com-
monly, but not always coincidentally, reactivate after
HSCT. We proposed that several modifications to the
GD2.CAR-modified VST generation protocol would also
improve the ability of the modified T-cells to expand and
persist in recipients.
In the previous study [1], EBVSTs were generated by
stimulation of PBMCs with irradiated, autologous EBV-
transformed B lymphoblastoid cell lines (EBV-LCLs). IL-2,
the cytokine used for EBVST expansion, was not intro-
duced until day 13 to ensure EBV specificity and optimal
transduction efficacy (40% to 50%), could not be achieved
until day 19 of culture (late transduction) at which time
the rate of T-cell proliferation was at its peak. However, by
this time significant in vitro differentiation had occurred
with loss of T-cells with an early-differentiated phenotype
(CD45RO+ CCR7+, central memory cells and CD45RO+,
CCR7−, CD62L+, T-cells with an intermediate phenotype),
while most T-cells had an effector memory (CD45RO+
CCR7−, CD62L−) phenotype. Moreover, after transduction,yright.
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obtain sufficient cells for infusion, and during this time, the
frequency of transduced T-cells often decreased, while the
population continued to differentiate. This prolonged
30-day ex vivo culture may have adversely impacted subse-
quent T cell proliferation in vivo. These issues may explain
the lack of in vivo proliferation we observed in a recent
clinical trial that evaluated triVSTs transduced with a sec-
ond generation CD19.CAR for the treatment of patients
with lymphoma after allogeneic HSCT [7]. In this study,
T-cells were also transduced after their third antigenic
stimulation on day 19. We proposed that lack of in vivo
expansion could result from late transduction of VSTs with
insufficient proliferative potential.
Here we describe a new strategy for the early retroviral
transduction of minimally differentiated triVSTs that
produces high and stable levels of transgene expression
in all three VST components and allows rapid expansion
to numbers sufficient for infusion within 8 to 16 days of
culture.
Results
For the new study we wished to transduce VSTs with a
less differentiated, preferentially central memory pheno-
type in the hope that they would have greater potential
to proliferate after infusion. We hypothesized that by in-













Figure 1 Optimization of early transduction of EBVSTs with a retrovir
EBV-LCLs with or without IL-4 and IL-7. Two days later, the cells were trans
(GFP) expression by EBVSTs transduced (A) on day 2 (ET) or (B) on day 19
indicated. (C) Show the total cell numbers of Day 2 (ET) transduced cells in
the mean +/− sd of 2 donors.be able to transduce VSTs after their first stimulation
(early transduction) and cryopreserve them for infusion
on day 8 to 16 of culture versus day 30 or later for late
transduced VSTs. Further, to transduce T-cells with
specificity for three viruses we had to be sure that our
stimulation produced sufficient stimulation of all popu-
lations with similar kinetics. Hence, ex vivo measure of
success would be (1) high levels of transduction of VSTs
with specificities for all three viruses (EBV, CMV and
adenovirus), (2) stable gene expression over two to three
in vitro stimulation cycles, (3) sufficient transduced
VSTs for our clinical use by day 16 of culture, (4) trans-
duced VSTs with a central memory phenotype.
EBV-specific T-cells (EBVSTs) can be transduced effectively
on day 3 of culture
To enhance the transduction efficiency of VSTs on day 2
or day 3 we attempted to increase the potency of the
first PBMC stimulation without loss of virus specificity.
In pilot experiments, we used a high-titer GFP-encoding
retroviral vector to transduce EBVSTs. The transduction
efficiency was similar when measured 4 days after trans-
duction (about 40%) in PBMCs transduced 3 days after
their first stimulation with EBV-LCLs (early trans-
duction, ET) (Figure 1A) or 3 days after their third
stimulation on day 19 (late transduction, LT) (Figure 1B).
However, the transgene frequency in early transducedB
23 30 37
of culture
al vector encoding GFP. PBMCs were stimulated with autologous
duced with a high titer retroviral vector encoding GFP. The transgene
(LT) was determined by FACS analysis after the number of stimulations
the presence or absence of IL-4 and IL-7 over time. Data represent
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EBVSTs increased to more than 80% by day 14 after
transduction, reflecting the specific expansion of the EBV-
specific component of the culture and loss of irrelevant
PBMCs. By contrast, the frequency of transduced T-cells
in LT cultures showed little change following subsequent
stimulations; likely because there is little change in the fre-
quency of EBVSTs after the third stimulation.
Proliferation of transduced EBVSTs can be increased
without loss of viral specificity by stimulation in the
presence of IL-4 and IL-7
We have previously shown that the addition of the pro-
survival cytokines IL-4 and IL-7 (IL-4/7) during the first
stimulation of VSTs increases their rate of expansion and
broadens their TCR repertoire, in part by increasing their
expression of anti-apoptotic molecules like bcl2 and bclXL
[8]. Furthermore, IL4/7-grown VSTs have been tested in
two clinical trials and were successfully able to resolve
viral infections after HSCT [9,10]. We therefore evaluated
the effect of IL-4/7 added during the first stimulation of
PBMCs and at the time of transduction. While the initial
transduction efficiency when measured on day 4 was not
substantially affected by IL-4/7 (Figure 1A and B), there
was greater expansion of early-transduced EBVSTs cul-
tured with IL-4/7 than without cytokines (Figure 1C), po-
tentially allowing us to achieve clinically relevant numbers
of transduced EBVSTs more rapidly.
Having established that EBVSTs can be transduced ef-
ficiently after their first stimulation with a high titer GFP
control retroviral vector, we next explored early trans-
duction of EBVSTs with the less efficient, clinical grade
first generation GD2.CAR retroviral vector that was to
be used in the proposed clinical trial. In these experi-
ments transduction efficiency was higher in EBVSTs
transduced on day 3 (mean 20%; range 15.94% to 24.5%)
(Figure 2A) than in EBVSTs transduced on day 19 (mean
10.1%; range 7.73% to 12.5%) (Figure 2B). Furthermore,
the increase in the frequency of transduced cells in day
3-transduced EBVSTs to mean of 66% (range 63% to
69%) upon subsequent stimulations was not observed in
day 19-transduced EBVSTs (mean 13%; range 6.6% to
19.6%).
To validate these phenotypic measures of transduction
efficiencies, we used RT-PCR 5 to 8 days post-transduction
to measure the integrated retroviral copy numbers and
compared these transduction efficiencies to those achieved
in the patient-derived EBVSTs used in our earlier clinical
trial [1]. Day 19 transduced EBVSTs and the patient
EBVSTs exhibited similar GD2.CAR transduction efficien-
cies (14,816 copies ± 4191 copies and 17,450 ± 10,632, per
μg DNA respectively), while day 3-transduced EBVSTs had
much higher GD2.CAR transduction efficiencies (81,983
copies ± 12,572 copies per μg DNA) (Figure 2C). Consis-
tent with their expression of the GD2.CAR, both early andlate-transduced EBVSTs killed GD2-positive LAN1 neuro-
blastoma cells, whilst retaining their ability to kill auto-
logous EBV-LCLs through their MHC-restricted native
TCRs (Figure 2D).
Early transduced T cells have a less differentiated
phenotype than late-transduced T-cells
Since VSTs transduced on day 3 can potentially be cryo-
preserved for infusion at the end of their first (days 9 to
11) or second (day 16 to 18) proliferative cycles, they are
likely to be less differentiated than VSTs transduced on
day 19, after their third stimulation and cryopreserved
for infusion at the earliest on day 26. Therefore, we ana-
lyzed Day 3- and Day 19-transduced VSTs for markers
of T-cell differentiation (CD45RO, CD62L, and CCR7)
to determine the differentiation state of the CAR-positive
VSTs at the time of cryopreservation (day 11 for Day 3-
transduced VSTs and day 26 for Day 19-transduced
VSTs). In 5 of 6 donors, day 3-transduced VSTs contained
a higher percentage of central memory cells expressing
both CD62L and CCR7 (Figure 3A and B), supporting our
hypothesis that early transduction enables transduction of
a cell product with a less differentiated state and likely
greater memory potential. Of note, day 3 transduction of
VSTs produced cultures in which both CD4+ and CD8+
VSTs were transduced, while transducing on Day 19
sometimes favored the transduction of either CD4+ or
CD8+ cells(Figure 3C).
Simultaneous induction of trivirus-specific T-cells (triVSTs)
The proposed clinical trial called for the preparation of
GD2.CAR-transduced T-cells specific for CMV, EBV and
adenovirus. Although we had previously generated (non-
transduced) triVSTs for clinical use [11], the first sti-
mulation of PBMCs was with Ad5f35-pp65-transduced
monocytes or dendritic cells that provided CMV pp65 as
a transgene and processed and presented adenovirus
hexon and penton from the virion, EBV antigens were
not introduced until day 9, when the VSTs were restimu-
lated with Ad5f35-transduced EBV-LCLs (Figure 4A).
Early transduction of triVSTs requires that PBMCs be
stimulated with similar kinetics and potency with anti-
gens from all three viruses. Therefore, we compared two
methods of presenting antigens from all three viruses to
PBMCs from CMV and EBV-seropositive donors. In the
first method, PBMCs were adhered to plastic overnight to
activate monocytes then were transduced with Ad5F35-
pp65 and cocultured with EBV-LCLs (Ad/PBMC+ LCL
method Figure 4B, top). In the second method, EBV-LCLs
were transduced with Ad5F35-pp65, irradiated and cocul-
tured with PBMCs at a stimulator to responder ratios of
(40:1) (Ad/LCL method Figure 4B, bottom). For the
Ad/PBMC+ LCL method, we tested different multiplici-







Figure 2 Early transduction of EBVSTs with GD2.CAR vector. PBMCs were stimulated four times with irradiated autologous LCLs on days 0, 9,
16 and 23 of culture. They were transduced with the GD2.CAR retroviral vector either on day 3 or day 19. GD2.CAR transgene levels were
measured by flow cytometry on (A) day 3- early transduced (ET) or (B) day 19 late-transduced (LT) EBVSTs at the end of each stimulation. Data
represent the mean +/− sd of 2 donors. (C) The transduction efficiency of ET or LT cells was compared with patient-derived EBVSTs (transduced
on day ~19) from the previous clinical trial [1] using real-time PCR analysis for the retroviral vector. Day 19-transduced (LT) EBVSTs and patient
lines demonstrated similar transduction efficiencies while Day 3-transduced (ET) EBVSTs attained a much higher transgene expression. Transgene
PCR was performed 5 to 8 days post-transduction. (D) Specific killing was determined in a 6-hour 51Chromium-release assay using the GD2
expressing neuroblastoma cell line, LAN-1 (top), and autologous LCL (bottom).
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(103 and 104 vp per cell) and different Ad/PBMC:LCL ra-
tios (40:1 and 100:1), and found that all conditions in-
duced T-cells specific for all three viruses and there was
little difference between any of the conditions (Figure 4C).
T-cells specific for all three viruses were also activated
using the Ad/LCL method (Figure 4C), which induced
greater expansion of triVSTs than the Ad/PBMC+ LCL
method (Figure 4D). Since this method was simpler than
the Ad/PBMCs + LCL method, we elected to use the
Ad/LCL method for our clinical standard operating pro-
cedure (SOP).
We further optimized Ad5f35-pp65 transduction of
EBV-LCLs by comparing Ad5f35 MOIs of 103, 104, and
105. MOI’s of 104 and 105 vps per cell produced higherT-cell responses to all three viruses than the MOI of 103
(Figure 5A) and since there was little difference between
the two higher ratios, an MOI of 104 was used for the
clinical standard operating procedure (SOP). Since we
were concerned that the different kinetics of antigen
presentation of the pp65 transgene, the virion proteins
of the vector and the pre-existing EBV genes would lead
to competition between the different epitopes on the
antigen presenting LCLs, we also explored the optimum
time for Ad5f35-pp65 transduction of LCLs prior to
their use as APCs. However, we found little difference
whether they were transduced 5 hours, 24 hours or
48 hours prior to coculture with PBMCs (Figure 5B).
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Figure 3 The effector memory phenotype of T-cells transduced on day 3 and day 19. The phenotype of Day 3 (early) and Day 19
(late)-transduced VSTs was determined by flow cytometry after staining for CD3, CD45RO, CD62L, CCR7, CD8 and the GD2.CAR. (A) Gating of
T cell memory subsets. CD3+GD2.CAR+ CD45RO+ cells were gated and their memory phenotype classified based on differential expression of
CD62L and CCR7. Representative dot-plots from one donor out of six are shown (B). Percentages of CD62L+CCR7+ central memory cells,
CD62L+CCR7− intermediate, CD62L−CCR7− effector memory T cells were gated as above in six donors. (C) The frequency of CD4+ and CD8+ cells
in the CD3+GD2.CAR+ gate. The analysis of the phenotype was performed at the time of potential cryopreservation (day 11 for Day 3 transduced
VSTs and day 26 for Day 19 transduced VSTs).
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our clinical SOP. As in our previous study, the fraction
of T-cells specific for CMV-pp65 was greater than for
adenovirus or EBV, reflecting the generally higher pre-
cursor frequency of CMV-specific T-cells in circulation
[12,13].
We also found that the prolonged culture of tri-virus
specific T cells led to skewing responses to more domi-
nant antigens, such as pp65 (Figure 5C) compared to
EBV and adenovirus. This is clear after the thirdstimulation (day 25), when adenovirus and EBV-specific
responses were diminished. Therefore early transduction
and cryopreservation of tri-VSTs after one or two stimu-
lations allow balanced specificity for all three viruses.
T-cells specific for CMV, adenovirus and EBV are similarly
transduced with the GD2.CAR vector
To ensure that each virus-specific component of the
triVSTs elicited by Ad-LCLs could be transducedyright.
















Figure 4 Simultaneous induction of trivirus-specific T-cells. (A) A diagram depicting the standard protocol for the generation of triVSTs.
(B) Comparison of two protocols for the simultaneous induction of triVSTs. In Ad/PBMC + LCL protocol, PBMCs were cultured in non-tissue culture
treated plates overnight then transduced with Ad5f35-pp65 and cocultured with autologous LCLs. In the Ad/LCL protocol, LCLs were transduced
with the Ad5f35-pp65 vector and used for autologous PBMC stimulation. (C) Day 9 after the first stimulation, the AdV (hexon and penton), CMV
(pp65) and EBV (Auto LCL) specificities were determined by ELIspot assay using pepmixes for hexon, penton and pp65 and autologous LCLs
for EBV. The MOI of Ad5f35-pp65 transduction and the ratio of PBMC to LCL are indicated. (D) TriVSTs were generated using Ad/LCLs and
Ad/PBMC + LCLs (100:1) and counted on days 3, 10, and 14. Data represent the mean +/− sd of 2 donors.
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efficiently, PBMCs stimulated with Ad5f35-pp65-transduced
LCLs in the presence of IL-4 and IL-7 were transduced on
day 2 and then analyzed for dual specificity for a viral epi-
tope and the GD2-CAR by flow cytometry. The triVST
line shown in Figure 6A had specificity for all three viruses
detectable by pentamer analysis (Figure 6A left panel).
The pentamer positive populations were gated andanalyzed for their expression of the GD2.CAR. Figure 6A
(right panel) shows the coexpression of the GD2.CAR on
81% of CMV (HLA A2-NLV) pentamer + T-cells, 88% of
EBV (HLA A2-CLG) pentamer-positive T-cells, and 79%
of AdV (HLA A24-TYF)-pentamer positive VSTs.
To confirm that endogenous TCRs in CAR-transduced
























Figure 5 Optimization of the induction of trivirus specificity
with Ad5f35-pp65 transduced LCL. (A) Trivirus specificity was
determined by γ-IFN ELIspot assay 9 days after the 1st stimulation.
The MOIs of Ad5f35-pp65 transduction of LCLs were 103, 104, and
105 vp per cell respectively. (B) LCLs were transduced with an MOI
of 104 and cultured for the indicated times before being irradiated
and used for PBMC stimulation. ELIspot assays were performed 9 days
after the 1st stimulation. Non-transduced (NT) LCLs were used as
controls. Data represent the mean +/− sd of 2 donors. (C) Tri-virus
specific CTLs were initiated on Day 0 and re-stimulated on Days 9
and 18. Tri-virus specificities were assessed by γ-IFN ELIspot assay
with LCLs or overlapping libraries of pepmixes spanning adenovirus
hexon and penton and CMV pp65 proteins.
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with cognate antigens, we tested GD2.CAR-transduced
and non-transduced T cells from three donors in IFN-γ
ELISPOT assays with serial dilutions of peptide libraries
(pepmixes) spanning hexon, pp65 and LMP2 proteins.
There was no significant difference (p > 0.05) between
responses in non-transduced and CAR-VSTs (Figure 6B
and Additional file 1: Figure S1). Further, there was no
significant difference (p > 0.05) in frequency (99.3% ± 0.4%
in CAR-transduced VSTs and 99.4% ± 0.4%, n = 3) of
αβTCRs in GD2.CAR transduced and non-transduced
cells from three donors.
VST transduction efficiencies can be increased by
centrifugation of retroviral supernatant onto
retronectin-coated plates
We next determined if centrifugation of viral super-
natant onto retronectin-coated plates for two hours at
2000 × G as recommended by Takara Bio, would im-
prove the transduction efficiency of triVSTs. After the
centrifugation, the retroviral supernatant was removed
prior to plating the triVSTs in medium with cytokines.
The centrifugation step significantly increased transduc-
tion efficiency from mean of 22 (range 18% to 25%) to
mean of 55% (range 52% to 58%) (Figure 6C) and the
centrifugation time could be reduced to one hour with-
out loss of transduction efficiency (Figure 6D). Of note,
the removal of the retroviral supernatant after centrifu-
gation increased the rate of expansion of VSTs after
transduction, without compromising the transduction ef-
ficiency (not shown), likely reflecting removal of inhibi-
tory factors present in the crude supernatant.
CAR expression is increased by TCR stimulation
While GD2.CAR was stable in early transduced T-cells
over time, the percentage of CAR+ cells increased in re-
sponse to TCR stimulation after 48 hours of culture
without cytokines in both CD4+ and CD8+ populations
of early and late-transduced triVSTs (Figure 6E and
Additional file 1: Figure S2). The upregulation of CAR


































































Figure 6 Improving the efficiency of the TriVST transduction. (A) PBMCs were stimulated using the Ad/LCL protocol in the presence of IL-4
and IL-7 and transduced on day 3 with the GD2.CAR vector. Co-expression of the GD2.CAR on pentamer positive CMV (A2-NLV), EBV (A2-CLG)
and AdV (A24-TYF)-specific T-cells was analyzed by flow cytometry after the 3rd stimulation to confirm the transduction of triVSTs. The dot plots
of one representative donor are shown. (B) GD2.CAR-transduced and non-transduced triVSTs from three donors were analyzed in IFN-γ ELISPOT
with serial dilutions of overlapping pepmix library spanning adenovirus hexon. Responses were analyzed by two-way ANOVA and no statistical
significant difference (p > 0.5) between transduced and non-transduced cells were found (C) The transduction efficiency with or without
centrifugation of the retrovirus vector at 2000 × G onto the retronectin-coated plates is shown. (D) The transduction efficiency of VSTs after the
indicated centrifugation time for the retroviral supernatant. Data represent the mean +/− sd of 2 donors. (E) Surface expression levels of GD2.CAR
were upregulated in early transduced (ET) CD4+ and CD8+ T cells (left panel) and in late transduced (LT, right panel) triVSTs upon stimulation with
LCLs and LCLs transduced with Ad5f35-pp65 (LCL Adpp65) for 48 hours without cytokines. Results are shown as mean ± SD, n = 3.
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transduced VSTs were likely more activated and thus
had higher basal expression of the transgene. This is
consistent with our previous observations on enrichment
of CAR-expressing EBVSTs upon stimulation with LCLs
[14] and further strengthens the rationale for using VSTs
as hosts for tumor-specific CARs.Early transduced triVSTs produce multiple cytokines and
have higher proliferative capacity than late-transduced
triVSTs
We compared cytokine production by early and late-
transduced VSTs after stimulation with a pp65 pepmix
and Ad-pp65 transduced LCLs for 24 hours in ayright.




ancer: first published as 10.1186/s404cytokine multiplex assay. Early-transduced VSTs pro-
duced higher levels of IFN-γ, TNFα, IL-2, GM-CSF,
MIP-1α, MIP-1β, IL-3, IL-5, IL-8, IL-10, IL-13, IFN-α2,
fractalkine, VEGF and sCD40L (Figure 7 and data not
shown). By contrast, late transduced triVSTs produced
higher levels of TNF-β and chemokines CXCL10 (IP-10)
and CCL22 (MDC) (Additional file 1: Figure S3).
To compare the proliferative potential of early and
late-transduced T-cells we performed eFluor dilution
assays in CAR-triVSTs co-cultured with the GD2-positive
neuroblastoma cell line LAN-1, LCLs and LCLs-
transduced with Ad-pp65. Figure 8 shows greater prolife-


































































Figure 7 Cytokines predominantly produced by early differentiated t
donors were stimulated with the pp65 pepmix or 2.5×105 autologous LCLs
after the stimulation and analyzed for multiple cytokines using multiplex cyVSTs in response to both CAR and TCR stimulation.
CD8+ early-transduced VSTs proliferated significantly
more (p = 0.0067) in response to LCLs compared to late-
transduced VSTs (Additional file 1: Figure S4). Together
these data suggest that the function and proliferative
potential of early transduced VSTs may be greater than
that of late-transduced VSTs.
Validation of GMP-compliant GD2.CAR-modified triVST
production
Finally, to validate our optimized procedure in our
cGMP facility, PBMCs from blood bank-eligible donors
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riVSTs. One million early (ET) or late (LT) transduced triVSTs from two
transduced with Ad5f35-pp65. Supernatants were collected 24 hours
tokine magnetic bead assay.
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Figure 8 Improved proliferation of early transduced triVSTs. Early transduced (ET) and late transduced (LT) triVST with retrovirus expressing
GD2.CAR were co-cultured for 72 hours with (A) GD2-positive LAN-1 neuroblastoma cells, or with (B) autologous LCLs at 4:1 of VST to LCL ratio
or (C) Ad5f35-pp65-transduced LCLs (LCL-Adpp65). Proliferation of CD3+ T cells was evaluated by eFluor dilution by flow cytometry. Histograms
are representative results from one donor. Cell division indexes were calculated using FlowJo software. Results are shown as mean ± SD, n = 3.
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stimulated at a PBMC to Ad/LCL ratio of 40:1 on Day 0
at an MOI of 104 vp per cell and supplemented with
400 U/mL IL-4 and 10 ng/mL IL-7 (IL-4/7). On day 3 of
culture T cells were transduced with the GD2.CAR
retroviral vector in the presence of fresh IL-4 and IL-7.
Transduced triVSTs were harvested on Day 9 and re-
stimulated at a 5:1 ratio of Ad5f35-pp65-transduced
LCLs:VSTs in a gas permeable G-Rex flask with IL-4
and IL-7. IL-2 (50 U/ml) was added after the second
stimulation every 3 to 4 days starting on day 12 and the
cells were cryopreserved on day 16–18 when sufficient
triVSTs for potential clinical use was obtained. During
the first stimulation, we obtained 5.4 ± 1.8-fold (N = 3) T
cell expansion. For example, starting with 24 × 106
PBMCs, we obtained 173 × 106 triVSTs on day 8. Trans-
duced triVSTs expanded by 178 ± 110-fold during the
second stimulation, increasing from 2 × 106 on day 8 to
231 × 106 on day 16. The average total expansion duringtwo stimulations was 961.2-fold. Since triVST precursors
constitute only a small fraction of total PBMCs, the true
fold expansion of VSTs was likely at least 100-fold
greater than reflected by the bulk expansion. A sche-
matic of the validation run is shown in Figure 9A. Of
note, since very small numbers of VSTs (2 × 107 triVSTs
per m2) are required in the HSCT setting, sufficient
GD2.CAR-modified triVSTs were obtained on day 9 for
potential clinical use.
During the validation runs, transgene expression in-
creased from 61 ± 25% (mean ± sd) after the first stimula-
tion to 78 ± 20% after the second stimulation (Figure 9B).
T-cells specific for all three viruses were detected by IFN-
γ ELISPOT assay after both the first and second stimu-
lations (Figure 9C). Of note, slightly greater expansion
and a higher transduction efficiencies were obtained in
the validation runs, compared to research expansions,
likely reflecting the modified medium formulation used inyright.
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Figure 9 GMP validation of the SOP for early transduction of TriVSTs. (A) Diagram of the finalized SOP. Day 0, PBMC were stimulated with
irradiated, Ad5f35-transduced autologous LCLs and then transduced on day 3. On day 9, triVSTs were harvested and restimulated in a G-Rex100
gas permeable flask. Cryopreservation was performed after the second stimulation on days 16–18 of culture. (B) Transgene expression after the
1st and 2nd stimulation was determined by flow cytometry in 4 donors. (C) Trivirus specificity was determined by γ-IFN ELIspot assay after the 1st
and 2nd stimulations. 1x105 responder cells per well were pulsed with overlapping peptide libraries for hexon, penton (to test for adenovirus
specificity) and pp65 (to test for CMV specificity) and LCLs (to test for EBV specificity). One representative donor of three is shown. (D) Three
clinical products of CAR-transduced triVSTs were cryopreserved in 10% DMSO, 12.5% HSA (Flexbumin, Baxter) and 1xHBSS in a Cryomed
controlled-rate freezer. Viability of fresh and thawed cells was evaluated using trypan blue exclusion method. (E) INF-γ ELISPOT assay results for
fresh and thawed CAR-transduced tri-VSTs. Adenovirus-specific responses were evaluated using pepmix libraries spanning hexon and penton,
CMV with a pepmix library for pp65 and EBV-specific responses were analyzed using autologous LCLs.
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our GMP facility in which RPMI-1640 was replaced with
Advanced RPMI. The average viability of infusion-grade
triVSTs at the time of cryopreservation was 97.7% ± 0.6%
(n = 3) (Figure 9D), which was greater than the 70% re-
lease criterion for clinical products. To evaluate potential
viability and function after infusion, CAR-modified
triVSTs were thawed (viability was 84.2% ± 8%) and cul-
tured overnight before testing specificity in IFN-γ ELI-
SPOT assays (Figure 9E). All products retained their
responses to adenovirus (hexon and penton pepmixes),CMV (pp65) and EBV (LCLs), although in two donors the
responses were lower than in fresh cells (Figure 9E left
panel and data not shown) while in the other, responses to
adenovirus proteins and pp65 were augmented (Figure 9E
right panel) in thawed cells.
Discussion
VSTs have the potential to proliferate extensively after
infusion into T-cell-depleted HSCT recipients and to
control the viral infections to which these patients areyright.
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susceptible [9,10,15,16]. If these proliferating VSTs ex-
press a transgenic tumor-specific CAR as well as their
TCR, then viruses should be able to increase their fre-
quency, even if the tumors targeted by the CAR are
poorly immunogenic or immunosuppressive. With the
ultimate goal of producing CAR-modified VSTs with a
central memory phenotype and hence the potential to
proliferate extensively after infusion and to persist long
term we have developed and optimized a GMP com-
pliant strategy for the early transduction of triVSTs.
Stimulation of PBMCs with irradiated, autologous LCLs
transduced with an adenovirus vector expressing the
pp65 protein of CMV allowed the presentation of anti-
gens from all three viruses with kinetics that enabled
their simultaneous transduction on day 3 as demon-
strated by the expression of a GD2.CAR on pentamer-
positive T-cells. Transduction on day 3 and the addition
of prosurvival cytokines allowed rapid expansion and
early cryopreservation of GD2.CAR-modfied triVSTs for
use in a clinical trial in patients who have received T-cell
depleted HSCT for multiply relapsed neuroblastoma. On
day 3 of culture, VSTs with a central memory phenotype
could be transduced, and CD45RO+ CCR7+ CD62L+
central memory transduced VSTs remained in the cultures
at the end of the first stimulation. Early-transduced
T-cells should have a greater potential to proliferate, eli-
minate tumors, and enter the memory compartment than
VSTs transduced on day 19 at which time the majority of
cells have lost expression of CCR7 and have an effector
memory phenotype. Hence, we propose that GD2.CAR-
modified T-cells specific for CMV, EBV and adenovirus
should be effective both for the prevention and treatment
of the three most common viral infections of HSCT recip-
ients and for the treatment of neuroblastoma.
It is clear that the anti-tumor efficacy of adoptively-
transferred tumor-specific T-cells requires extensive
in vivo proliferation and long-term persistence since
tumor eradication may take several weeks or months. It
is also important that infused T-cells enter the memory
compartment so that they can prevent the outgrowth of
dormant tumors over the patient’s life-time. Such proli-
feration requires potent in vivo stimulation, not only
with antigen via the CAR or the TCR, but also via costi-
mulatory receptors and cytokines. However, even if they
have not downregulated HLA antigens, most tumors do
not present antigens in an immunostimulatory fashion.
They lack costimulatory molecules and/or express in-
hibitory ligands and cytokines that inhibit T-cells and
subvert the functions of local professional APCs. There-
fore infused tumor-specific T-cells are unlikely to receive
adequate stimulation after infusion. CD19.CAR T-cells,
which have been particularly successful in the clinic
[17,18], may be an exception since the B-cells they target
are professional antigen presenting cells and expresscostimulatory molecules, as do normal B-cells that are
also targets for CD19.CARs. Even when costimulatory
domains are included in the CAR so that transduced
cells receive intrinsic costimulation upon ligation of the
CAR, cytokines are usually lacking, and the T-cells fre-
quently fail to proliferate extensively. Cytokines can be
infused, but are toxic and can enhance the proliferation
of T regulatory cells [19]. Consequently, most groups
use cytotoxic lymphodepletion to promote the subse-
quent homeostatic proliferation of adoptively transferred
CAR.T-cells [18].
By contrast to tumors, most viral infections are highly
immunostimulatory, since not only are viral antigens
presented to the immune system, but viral structures
such as virion proteins and viral nucleic acids provide
pattern-associated molecular patterns (PAMPs) that acti-
vate innate immune responses that coordinate and amp-
lify the adaptive immune response. After T-cell-depleted
HSCT, the recipient is lymphopenic so that homeostatic
cytokines are abundant and endogenous viruses fre-
quently reactivate providing the ideal conditions for VST
expansion. However, even after HSCT, in the absence of
active infection or virus reactivation, little VST expan-
sion may occur and we have observed minimal expan-
sion of adenovirus-specific T-cells in the absence of
adenovirus infection, while T-cells specific for EBV and
CMV that establish persistent infections almost always
expand, with the degree of expansion correlating with
virus load [9,11]. After HSCT therefore, triVSTs express-
ing a first generation GD2.CAR (without co-stimulatory
endodomains) should receive effective in vivo costimula-
tion from professional APCs presenting antigens from
endogenous EBV and CMV, and from adenovirus if the
patient has such an infection. Since not all patients
reactivate all viruses, increasing the number of viruses
targeted by CAR-T-cells will increase the chances for
stimulation.
We have previously demonstrated the clinical anti-
viral efficacy of triVSTs [11]. However our manufac-
turing SOP comprised an initial stimulation of PBMCs
using monocytes transduced with an adenoviral vector
expressing pp65 of CMV (Ad5f35-pp65), while the EBV-
specific component was not activated until day 9, when
the cultures were restimulated with autologous EBV-
LCLs transduced with Ad5f35-pp65. Therefore, this SOP
required considerable modification to achieve transduc-
tion of T-cells specific for all three viruses on day 3 of
culture. The simplest most effective APCs proved to be
Ad5f35-pp65-transduced LCLs. LCLs are potent APCs
since they express a range of costimulatory molecules,
and they are excellent feeder cells that can be transduced
with adenovirus type 5 provided it has a chimeric fiber
with elements of Ad35 that allows transduction via
CD46 [11,20]. Although the Ad vector does not expressyright.
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its genome, LCLs effectively process and present hexon
and penton, the most abundant virion proteins, to
AdVSTs, and such T-cells have been shown to control
Ad infections [11,21]. CMV-pp65, expressed as a trans-
gene is efficiently processed and presented to T-cells by
transduced LCLs.
In our previous studies using gene-modified VSTs,
[1,7,14,22,23] we routinely performed transduction on
day 19, three days after the third stimulation, at which
time VSTs were proliferating sufficiently well to produce
reasonable transduction efficiencies, whereas transduc-
tion after the first stimulation produced low levels of
transduction. In this work we have used the IL-4 and
IL-7 for expansion of triVSTs in vitro, because this com-
bination of cytokines promoted survival and expansion
of VSTs without loss of specificity and induced high
frequencies of viral antigen-specific IFNγ-producing T
cells both in CD4+ and CD8+ T cell, at levels substan-
tially higher than T cells generated with other cytokines,
such as IL-15 and IL-2 [8]. In addition, improved media
formulations (Click’s medium combined with RPMI-1640
or Advanced RPMI-1640) and the adoption of the retro-
viral vector centrifugation step enabled us to obtain high
levels of retrovirus transduction of VSTs even with a less
than optimal vector. Transduction levels of 30 to 40%
were observed within a few days of transduction, when
irrelevant T-cells remained in the cultures, and increased
to up to 90% after antigen-driven T-cell expansion.
Our GMP compliant method for the early transduc-
tion of triVSTs providing the possibility of cryopreserva-
tion after a single stimulation is attractive as it allows for
the clinical use of less differentiated VSTs and requires
significantly less GMP manufacturing time. The re-
quirement for a second stimulation is dependent on the
starting PBMC number, the rate of VST expansion, the
patient size and dose and the number of doses allowed.
We observed an average of 5.4 ± 1.8-fold expansion after
a single stimulation, so that 25 × 106 PBMCs from about
25 mLs of blood could produce about 142 × 106 triVSTs
after 9 days in culture, more than sufficient for the pro-
posed clinical trial (NCT01460901).
The GMP validation of our new cell production strat-
egy yielded even higher levels of transduction than the
preclinical studies. We ascribe this to the replacement of
RPMI-1640 with Advanced RPMI that enhances the rate
of T-cell expansion (not shown). TriVSTs cultured in
this medium (45% advanced RPMI, 45% Click’s medium
and 10% fetal bovine serum (FBS) produced over 80%
transduction after the second stimulation and over 60%
after the first stimulation in every case. Centrifugation of
the retroviral vector onto the retronectin-coated plates
also improved transduction and reduced the volume of
vector supernatant required from 5 mLs to 2 mLs per
1 × 106 T-cells. We also noted that removal of thesupernatant increased the subsequent rate of T-cell ex-
pansion without loss of transduction efficiency, likely
due to the removal of inhibitory factors in the vector
supernatant.
Conclusions
We developed a rapid and GMP compliant method for
the early transduction of multivirus-specific T-cells that
allowed stable expression of high levels of a tumor di-
rected CAR. Perhaps the most important outcome of the
optimization study was the transduction of VSTs with a
central memory phenotype. Such T-cells have the poten-
tial to cycle indefinitely and repopulate both effector and
memory populations, and T cells derived from this
population have been shown to be more efficacious after
adoptive T cell transfer [24-26]. Our earlier studies using
late transduction produced lower levels of transduction
of VSTs that could not be maintained during prolonged
culture, although low levels of transgene could be de-
tected years after infusion, suggesting that even when
transduced late, at least some T-cells maintained mem-
ory potential. However, the true value of these improve-
ments will be determined only by monitoring patients
on the clinical trial.
Methods
Cells and cell lines
Blood was obtained from healthy volunteers with informed
consent on a Baylor College of Medicine IRB-approved
protocol and processed into PBMCs on lymphoprep
(Stemcell Technologies, Vancouver, BC) gradients. PBMCs
were used to manufacture EBV-LCLs (as previously des-
cribed [27]) and VSTs. K562 and LAN-1 cells were ob-
tained from the American Type Culture Collection
(Rockville, MD). LCLs and K562 cells were maintained in
RPMI 1640 (Hyclone, Logan, UT) with 10% fetal bovine
serum (FBS; HyClone) and 2 mM L-glutamine (GlutaMAX,
Invitrogen, Carlsbad, CA) while LAN-1 cells were cultured
in Dulbecco’s modified Eagle’s medium (BioWhittaker,
Walkersville, MD) supplemented with 10% fetal bovine
serum and 2 mM L-glutamine.
Viruses and vectors
The adenoviral vector expressing pp65 of CMV (Ad5f35-
pp65) and retroviral vector, SFG.14g2a.zeta5 (GD2.CAR)
encoding a first generation CAR that recognizes GD2 have
been previously described [1,11]. The high-titer GFP re-
troviral vector was produced by co-transfection of 293 T
cells with the MSCV-IRES-eGFP retroviral vector along
with the gag/pol expression plasmid PegPam3(−env), the
RD114 env expression plasmid RDF and MSCV vectors at
a ratio of 2:3:3, respectively, using the GeneJuice transfec-
tion reagent (Calbiochem, Gibbstown, NJ) as previously
described [28].yright.
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To generate EBVSTs, PBMCs were stimulated with irra-
diated (40 Gy) autologous LCLs at a 40:1 ratio of PBMC
to LCLs in T-cell media (45% RPMI 1640, Hyclone, 45%
EHAA, Irvine Scientific (Santa Ana, CA), 10% heat inac-
tivated FCS, Hyclone, and 2 mM L-glutamine, for the
validation experiments in the GMP, RPMI 1640 was re-
placed with 45% Advanced RPMI, Invitrogen). On day 9
and weekly thereafter, EBVSTs were restimulated with
irradiated LCLs at a 1:4 ratio and IL-2 (50U/ml) was added
twice weekly from day 13–14 [27]. IL-4 (400U/ml) and
IL-7 (10 ng/ml) both from R&D Systems (Minneapolis,
MN) were added at the time of the first and second stimu-
lations where indicated.
Two methods were compared for the generation of
monocultures specific for CMV, adenovirus and EBV
(triVSTs) and are described in the text and summarized in
Figure 4. For the first stimulation in the Ad/PBMC+ LCL
method, PBMCs were adhered to plastic overnight, then
transduced with Ad5f35-pp65 at the indicated virus par-
ticle to cell ratio for the indicated times at 37°C/5%CO2
and were then cocultured with LCLs (at the indicated
ratios) for 9 days. In the Ad/LCL method, PBMCs were
stimulated with Ad5f35-pp65-transduced LCL at a 40:1
ratio in T-cell medium containing 400 U/ml IL-4 and
10 ng/ml IL-7 in 24-well plates. For the second and subse-
quent stimulations on days 9, 16 and 23 the triVSTs were
cocultured with irradiated Ad5f35-pp65-transduced LCLs
at a 1:5 ratio (T cells : LCLs) in a G-Rex100 (Wilson-Wolf
Manufacturing, Minneapolis, MN). On second stimula-
tion, the VSTs received 10 ng/ml IL-7 and 400 U/ml IL-4,
and then IL-2 (50U/ml) 3–4 days after the second stimula-
tion and twice weekly thereafter.
Transduction of triVSTs
In our previous clinical trials, EBVSTs or triVSTs were
transduced on day 19 with a different method. Retroviral
supernatant was adhered to retronectin-coated coated
plates (0.5 mL for 30 minutes × 2), then 0.5 × 106
EBVSTs were resuspended in 1.5 mL of retroviral super-
natant and 0.5 mL of fresh medium and centrifuged for
5 minutes on the coated plates before culture. In the
current study, the transduction was performed either
early (three days after the first stimulation) or late (three
days after the third stimulation on day 19). In both
cases, 1.5 ml of retroviral supernatant was added per
well of a retronectin (Takara, Mountain View, CA)
coated, non-tissue culture-treated plates and centrifuged
at 2000 × G for 1 hour at 30°C to allow virus adherence
of the retronectin and removal of the possible inhibitory
factors that are present in retroviral supernatants. Fol-
lowing removal of the retroviral supernatant, 0.5 × 106
VSTs were added to each well in T-cell media containing
10 ng/ml IL-7 and 400 U/ml IL-4. The plates werecentrifuged at 1000 × G for 5 minutes at room temperature
and then incubated at 37°C/5%CO2 for an additional 7 days.
Expression of the GD2.CAR was assessed by flow cytome-
try using the 1A7 antibody 4–5 days later and at various
times during subsequent culture.
Flow Cytometry
Immunophenotyping
The GD2.CAR was detected with the idiotypic antibody
1A7 [29]. To detect peptide epitope-specific T-cells in
the triVSTs, we used unlabeled pentamers (Proimmune,
Sarasota, FL) comprising HLA-A*0201-NLVPMVATV
(from pp65 of CMV), HLA-A*0201-CLGGLLTMV (from
LMP2 of EBV) and A*2401-TYFSLNNKF (from hexon
of adenovirus). TriVSTs were incubated with unlabeled
pentamer followed by Pro5 Fluorotag (Proimmune) in
accordance with the manufacturer’s instructions. The
VSTs were stained with monoclonal antibodies to CD3,
CD45RO, CCR7, CD8, and CD4 (Becton Dickinson,
Franklin Lakes, NJ). Approximately 20,000 events from
each culture were acquired with a Gallios Flow Cytometer
and analyzed with Kaluza software (Beckman Coulter,
Brea, CA).
eFluor dilution assay
To measure T cell proliferation ET and LT triVSTs were
incubated with 3 μM eFluor670 according to manufac-
turer’s protocol (eBioScience). One million of T cells
were seeded per well of a 24-well plate with 2.5 × 105
LCLs or 2.5 × 105 Ad5f35pp65-transduced LCLs or 2 ×
105 of LAN-1 cells. T cells were stained with anti-CD3-
Alexa Fluor 750, CD8-FITC, CD4-PacBlue (Beckman
Coulter). Approximately 10,000 live (7AAD-negative,
CD3+) T cells were acquired and analyzed using FlowJo
software (Ashland, OR).
Elispot assay
Interferon-γ (IFNγ) release by triVSTs was assessed by
enzyme-linked immunospot (ELISPOT) assay. Serial di-
lutions of triVSTs were plated in triplicate, starting at
105 cells per well of a 96-well MultiScreen HTS IP plate
(EMD Millipore, Billerica, MA), and stimulated with
overlapping peptide libraries (pepmixes) (JPT Peptide
Technologies) spanning the entire protein sequences of
CMV-pp65, AdV-hexon and Ad-penton and autologous
LCLs. ELISPOT plates were developed as previously de-
scribed [20]. Plates were sent to Zellnet Consulting, New
York, NY for quantification. Results are expressed as
spot-forming cells per 105 cells (SFCs/105 cells).
Cytotoxicity assay
A standard 6-hour 51chromium-release assay at effector
to target (E:T) ratios of 40:1, 20:1, 10:1 and 5:1 was used
to assess the cytolytic activity of transduced VSTs [22].yright.
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Target cells were GD2-positive LAN-1 cells, autologous
LCLs, and K562 cells. The percent specific lysis was calcu-
lated as ([experimental release – spontaneous release]/
[maximum release – spontaneous release]) × 100.
DNA extraction and QPCR performance
DNA was extracted from transduced and non-transduced
triVSTs using QIAamp DNA Blood Mini Kit (QIAGEN,
Louisville, KY). QPCR was performed to determine trans-
gene levels in transduced T cell lines (transduction effi-
ciency). Transgene specific TaqMAN custom assays were
ordered from Life Technologies, Carlsbad, CA. QPCR was
performed on 7900HT QPCR machine using TaqMAN
Universal Mastermix (Life Technologies, Grand Island, NY)
according to manufacturer instructions. 100 ng of extracted
genomic DNA was used per reaction, QPCR was per-
formed in triplicates. Quantification was based on a stand-
ard curve prepared according to the ABI standard curve
manual (Applied Biosystems). Transgene carrying plasmid
dilutions were used to obtain a standard curve. The sensi-
tivity of the assay was 1 copy per reaction.
Culture and cryopreservation of clinical-grade VSTs
Clinical-grade VSTs were expanded in 45% advanced RPMI
(Invitrogen), 45% Click’s medium (IrvineScientific, Santa
Ana, CA) and 10% FBS (HyClone). Although it would be
desirable to remove serum our media for the production of
GMP products, we have yet to find a serum free medium
that supports the growth of virus-specific T-cells. We have
used highly characterized, heat-inactivated fetal calf serum
for the manufacture of clinical grade T-cells that have been
safely infused into hundreds of patients over the last
20 years, and since the fetal calf serum derives from
American herds maintained specially for the production of
fetal calf serum, there seems to be little likelihood of the
transfer of unknown microbial agents. For safety reasons at
the time of harvest and cryopreservation we wash cells
four times to remove the traces of FBS in the formulated
cell products. CAR-transduced triVSTs were cryopreserved
at 1 × 107 cells/mL in cryo-medium containing 12.5%
Human Albumin Flexbumin USP (Baxter Healthcare
Corporation, Westlake Village, CA), 10% DMSO (Bioniche
Pharma USA LLC, Lake Forest, IL) and 1×HBSS (Sigma
Aldrich Co, LLC, St Louis, MO) using a Cryomed 7454
programmable freezer (Thermo Fisher Scientific, Waltham,
MA). Cells were recovered from storage in vapor phase
liquid nitrogen and were analyzed for viability by trypan
blue.
Additional file
Additional file 1: Figure S1. GD2.CAR-transduced and non-transduced
tri-VSTs from three donors were analyzed in IFN-g ELISPOT assay with
titrated cognate peptides in duplicates. Serial dilutions of pepmix librariesspanning LMP2 (A) and CMV pp65 (B) proteins were used. Responses
were analyzed by two-way ANOVA and statistically significant difference
was found only for donor 3 at 50 and 25 ng/mL of pp65 (B), which may
be a result of a technical error. Figure S2. Upregulation of GD2.CAR
expression in CD4 + CD3+ and CD8+ CD3+ triVSTs, which were early (ET)
and late transduced (LT) with GD2.CAR retrovirus upon stimulation for
48 hours with autologous LCLs and LCLs transduced with Ad-pp65.
Representative results for one of three donors are shown. Figure S3.
Cytokine predominantly produced by late transduced tri-VSTs. One mil-
lion of early (ET) or late (LT) transduced tri-VSTs from two donors were
stimulated with pp65 overalpping pepmix library or 1×105 autologous
LCLs transduced with Ad5f35-pp65. Supernatants were collected 24 hours
after the stimulation and analyzed by multiple cytokines with multiplex
cytokine magnetic bead assay (EMD Millipore). Figure S4. Higher
proliferation in response to LCLs of both CD4+ and CD8+ CD3+ T cells
in early transduced (ET) cells compared to late-transduced (LT) cells.
(A) Histograms are representative eFluor dilution profiles with individual
divisions depicted in blue. Representative results from one of three
donors are shown. Individual divisions are highlighted in blue lines and
assigned by FlowJo analysis. (B) Cell division indexes were calculated
using FlowJo software. Results are shown as mean ± SD, n = 3.
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